Cas9 Stable Cell Line - Caov-3

The Cas9 Stable Cell Line - Caov-3 is a genetically engineered cell model derived from the human ovarian adenocarcinoma cell line Caov-3. This specialized cell line is modified to stably express CRISPR-associated protein 9 (Cas9), a key component of the CRISPR-Cas9 genome editing system. Cas9 integration into the Caov-3 genome enables precise, efficient, and targeted gene modification without the need for repeated transfections. The parental cell line of Caov-3 is derived from ovarian cancer tissue, making this stable Cas9 variant particularly valuable in oncology research. Its epithelial morphology, adherent growth characteristics, and well-defined genetic background provide a stable platform for studying gene function, disease mechanisms, and treatment responses. This cell line has been rigorously validated for Cas9 activity, ensuring high editing efficiency and minimal off-target effects, crucial for the reproducibility of functional genomics experiments.

The Cas9 Stable Cell Line - Caov-3 can serve as a versatile tool across multiple fields of biomedical research. In cancer biology, it facilitates large-scale gene knockout screening to identify ovarian cancer-specific tumor suppressor genes, oncogenes, and drug resistance mechanisms. Researchers use this cell line to mimic gene alterations (such as TP53 mutations or BRCA defects) to study tumor progression, metastasis, and sensitivity to platinum-based chemotherapy drugs. Furthermore, it supports high-throughput functional genomics research, enabling the screening of thousands of gene targets through the aggregation of CRISPR libraries to discover novel drivers of ovarian cancer or vulnerabilities to targeted therapies. Beyond oncology, this cell line also supports drug development by precisely editing genes to validate drug targets, assess off-target effects of candidate compounds, and develop personalized medicine solutions.